HEAL Initiative: Analgesic Development Initial Translational Efforts [Small Molecules and Biologics] (U19 Clinical Trial Not Allowed) | RFA NS 21 015

Opportunity Information: Apply for RFA NS 21 015

The HEAL Initiative: Analgesic Development Initial Translational Efforts [Small Molecules and Biologics] (U19, Clinical Trial Not Allowed) funding opportunity (RFA-NS-21-015) is an NIH cooperative agreement designed to push promising, non-addictive pain therapeutics through the early translational pipeline. It sits within the broader HEAL (Helping to End Addiction Long-term) Initiative, and its central purpose is to fund team-based programs that can generate the practical development foundations needed to move a potential analgesic forward, especially the kinds of enabling work that often sit between basic discovery and a more formal preclinical-to-clinical development track. The emphasis is on building and using solid assays, running screening efforts, and conducting early optimization so that a credible “hit” or “lead” therapeutic candidate emerges with enough supporting evidence to justify the next stage of development.

This FOA is specifically focused on small molecules and biologics and supports activities such as assay development and validation, screening campaigns to identify hits, and early medicinal chemistry or biologic optimization work to improve properties like potency, selectivity, and developability. It also explicitly welcomes projects that identify, develop, and validate pharmacodynamic markers of efficacy, since reliable markers can help demonstrate target engagement and functional impact in a way that makes later-stage decision-making much more rigorous. In the same vein, pharmacokinetic and pharmacokinetic/pharmacodynamic (PK/PD) studies are considered responsive, reflecting NIH’s interest in seeing early evidence that the candidate not only works in a test system but also has a plausible exposure-response relationship that can eventually translate into a therapeutic dosing strategy.

A key success metric for an awarded project is progress: by the end of the project period (up to five years), the work should advance a hit or lead to the point that it can meet the entry criteria for a downstream HEAL FOA, specifically RFA-NS-21-010 (the UG3/UH3 program for Non-addictive Analgesic Therapeutics Development, where clinical trials are optional). In other words, this U19 mechanism is meant to de-risk and mature projects so they are ready to “graduate” into the next development phase rather than remain stuck at a discovery stage. The FOA also makes it clear there is no renewal option, reinforcing that this is intended as a time-limited, milestone-driven push toward a concrete development handoff.

Applications are expected to present a rigorous biological rationale for the therapeutic concept and to rely on scientifically sound assays. If the link between the proposed target and the pain indication is not already supported by strong data, the application must include a convincing plan to generate that evidence. This includes establishing that the target is genuinely connected to the disease biology and that modulating the target’s activity is likely to produce a meaningful, beneficial outcome for the pain condition being addressed. In practice, that means reviewers will be looking for more than a speculative target; they will want a coherent strategy for target validation, translational relevance, and decision-quality data that can support progression to a development-focused program.

The FOA is intentionally broad regarding pain indications. It is not restricted to any single pain disorder or category, and it explicitly notes that projects addressing acute pain, chronic pain, neuropathic pain, musculoskeletal pain, headache disorders, osteoarthritis, diabetic neuropathy, chemotherapy-induced neuropathy, eye pain, sickle-cell pain, post-surgical pain, cancer pain, visceral pain, post-stroke pain, myofascial pain, and orofacial pain disorders (among others) may be considered. This breadth signals that NIH’s priority is not the particular clinical label but whether the proposed therapeutic approach is non-addictive, mechanistically grounded, and supported by a development plan capable of producing a credible lead candidate.

From an administrative and funding standpoint, this is a discretionary NIH opportunity using a cooperative agreement mechanism (U19). Cooperative agreements typically involve substantial NIH programmatic involvement compared to a standard grant, which often translates into closer coordination, clearer milestone expectations, and structured progress oversight. The listed award ceiling is up to $15,000,000, indicating this program is designed for sizable, multi-component, collaborative efforts rather than small, single-lab exploratory projects. The FOA was created on March 11, 2021, and the original closing date was April 22, 2022.

Eligibility is broad and includes many types of domestic U.S. organizations and governmental units, such as state, county, city or township governments, special district governments, independent school districts, public and state-controlled institutions of higher education, and federally recognized Native American tribal governments. It also allows nonprofit organizations (both 501(c)(3) and non-501(c)(3)), private institutions of higher education, for-profit organizations (other than small businesses), and small businesses. In addition, the FOA highlights several other eligible applicant categories, including Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, Hispanic-serving Institutions, HBCUs, Tribally Controlled Colleges and Universities, tribal governments that are not federally recognized, faith-based or community-based organizations, eligible federal agencies, U.S. territories or possessions, regional organizations, and even non-U.S. (foreign) entities.

Finally, the “Clinical Trial Not Allowed” designation is an important boundary: this FOA is intended for preclinical and translational development activities that stop short of conducting a clinical trial. The expected endpoint is a well-supported therapeutic lead, backed by validated assays and early translational evidence (including PD markers and PK/PD where appropriate), positioned to meet the bar for entry into the next HEAL analgesic development program within the five-year project window.

• The National Institutes of Health in the health, income security and social services sector is offering a public funding opportunity titled "HEAL Initiative: Analgesic Development Initial Translational Efforts [Small Molecules and Biologics] (U19 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.121, 93.213, 93.242, 93.273, 93.350, 93.846, 93.853, 93.865, 93.866, 93.867.
• This funding opportunity was created on 2021-03-11.
• Applicants must submit their applications by 2022-04-22. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $15,000,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA NS 21 015

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: